Bisoprolol in the treatment of chronic heart failure

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 431-439

  de Groote, Pascal ^a   Ennezat, Pierre Vladimir ^a   Mouquet, Fréderic ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Beta blocker; Bisoprolol; Chronic heart failure

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CARVEDILOL; DIURETIC AGENT; ENALAPRIL; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; PLACEBO; RENIN INHIBITOR;

ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DIURETIC THERAPY; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPOTENSION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; PROGNOSIS; RECEPTOR AFFINITY; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

EID: 35148872704     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Baxter AJ, Spensley A, Hildreth A, et al. 2002. Beta blockers in older persons with heart failure: tolerability and impact on quality of life. Heart, 88:611-4.
2. Bundkirchen A, Brixius K, Bolck B, et al. 2003. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol, 460:19-26.
3. Chatterjee SS. 1986. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol, 8 Suppl 11:S74-7.
4. CIBIS-II Investigators and Committees. 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet, 353:9-13.
5. CIBIS Investigators and Committees. 1994. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation, 90:1765-73.
6. Cleland JG, Daubert JC, Erdmann E, et al. 2005. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med, 352:1539-49.
7. de Groote P, Delour P, Lamblin N, et al. 2004. Effects of bisoprolol in patients with stable congestive heart failure. Ann Cardiol Angeiol (Paris), 53:167-70.
8. Dorow P, Bethge H, Tonnesmann U. 1986. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol, 31:143-7.
9. Dubach P, Myers J, Bonetti P, et al. 2002. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J, 143:676-83.
10. Ennezat PV, Ennezat CA, Vijayaraman P, et al. 2005. Dissociation between improvement in left ventricular performance and functional class in patients with chronic heart failure. J Cardiovasc Pharmacol, 46:262-8.
11. Erdmann E, Lechat P, Verkenne P, et al. 2001. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail, 3:469-79.
12. Flather MD, Shibata MC, Coats AJ, et al. 2005. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 26:215-25.
13. Funck-Brentano C, Lancar R, Hansen S, et al. 2001. Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). Am Heart J, 142:989-97.
14. Funck-Brentano C, Lancar R, Le Heuzey JY, et al. 2000. Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. Am Heart J, 139:262-71.
15. Galatius S, Gustafsson F, Atar D, et al. 2004. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure - a randomized comparison. Cardiology, 102:160-5.
16. Hunt SA, Abraham WT, Chin MH, et al. 2005. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 112:e154-235.
17. Kirch W, Rose I, Demers HG, et al. 1987. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet, 13:110-7.
18. Lechat P, Hulot JS, Escolano S, et al. 2001. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation, 103:1428-33.
19. Leizorovicz A, Lechat P, Cucherat M, et al. 2002. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies - CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J, 143:301-7.
20. Leopold G, Pabst J, Ungethum W, et al. 1986. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol, 26:616-21.
21. McGavin JK, Keating GM. 2002. Bisoprolol: a review of its use in chronic heart failure. Drugs, 62:2677-96.
22. MERIT-HF study group. 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). The Lancet, 353:2001-7.
23. Packer M, Coats AJ, Fowler MB, et al. 2001. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 344:1651-8.
24. Pfeffer MA, Braunwald E, Moye LA, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial, The SAVE Investigators. N Engl J Med, 327:669-77.
25. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 341:709-17.
26. Poole-Wilson PA, Swedberg K, Cleland JG, et al. 2003. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362:7-13.
27. Schuchert A. 2005. Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. Eur J Heart Fail, 7:604-11.
28. Simon T, Mary-Krause M, Funck-Brentano C, et al. 2003. Bisoprolol doseresponse relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J, 24:552-9.
29. Smith C, Teitler M. 1999. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther, 13:123-6.
30. Swedberg K, Cleland J, Dargie H, et al. 2005. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 26:1115-40.
31. Swedberg K, Hjalmarson A, Waagstein F, et al. 1979. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet, 1:1374-6.
32. The Beta-Blocker Evaluation of Survival Trial Investigators. 2001. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med, 344:1659-67.
33. The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med, 316:1429-35.
34. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med, 325:293-302.
35. The SOLVD Investigators. 1992. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med, 327:685-91.
36. Waagstein F, Hjalmarson A, Varnauskas E, et al. 1975. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J, 37:1022-36.
37. Wellstein A, Palm D, Belz GG, et al. 1986. Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. J Cardiovasc Pharmacol, 8(Suppl 11):S41-5.
38. Willenheimer R, van Veldhuisen DJ, Silke B, et al. 2005. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation, 112:2426-35.